Our findings extend this concept by developing an intravenous CpG7909 lipoplex that promotes CD8+ T-cell infiltration into the tumor microenvironment and demonstrates synergy with anti–PD-1 therapy in resistant, deep-seated, and metastatic models. This evidence concerns the gene CD8A and neoplasm.